Logo Image
|Articles|June 21, 2021

Evidence-Based Oncology

  • June 2021
  • Volume 27
  • Issue 4

Weidner et al, Appendices

Appendices to: Observations Regarding the Average Sales Price Reimbursement Methodology

eAPPENDICES Weidner et al

Articles in this issue

about 5 years ago

Dollars and Sense

about 5 years ago

FDA Panel Votes to Keep 4 of 6 “Dangling Approvals,” in a Sign of Things to Come

about 5 years ago

Observations Regarding the Average Sales Price Reimbursement Methodology

about 5 years ago

Real-World Evidence Is Key to Accelerating Oncology Approvals

about 5 years ago

PATHWAYS: Oncology Care Pathways Launched by Payers: What Are the Trends?

about 5 years ago

Biosimilars Drive Savings in Medicare’s Oncology Care Model

about 5 years ago

A Social Worker Leads ACCC, and Her Timing Is Perfect

over 5 years ago

After PD-1 Inhibitor Indications Are Withdrawn in SCLC, What Now?

Related Content